A Phase 2 Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Patient-Specific Immunotherapy, Recombinant Idiotype Conjugated to KLH (Id-KLH) and Administered With GM-CSF, in Patients With Follicular Non-Hodgkin's Lymphoma (fNHL) Following Primary Treatment With Rituximab and Chemotherapy (R-Chemo)

Inclusion Criteria:

1. Written informed consent

2. Previously untreated follicular NHL

3. Stage III or IV disease requiring treatment

4. Able to receive rituximab and chemotherapy (rituximab with cyclophosphamide,
vincristine, and prednisone either with or without doxorubicin)

5. Able to provide tumor sample adequate for Id-KLH manufacture

6. ≥ 18 years of age

7. At least one bi-dimensionally measurable lesion ≥ 2 cm by CT scan